German High-Grade Non-Hodgkin's Lymphoma Study Group
Quick facts
Phase 3 pipeline
- R-CHOEP 14 with 12x Rituximab · Oncology
R-CHOEP 14 with rituximab combines chemotherapy (cyclophosphamide, doxorubicin, etoposide, prednisone) with the anti-CD20 monoclonal antibody rituximab to kill lymphoma cells through chemotoxicity and antibody-mediated immune destruction.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: